Objectives: The Society for Vascular Surgery Wound Ischemia foot Infection classification (WIfI) was introduced in 2014 and has been validated in multiple institutional series as a useful tool to assess the severity of chronic limb-threatening ischemia (CLTI) and predict the risk of major amputation after lower extremity revascularization (LER). The Vascular Quality Initiative (VQI) peripheral vascular interventions (PVI) database captures data on wounds, ischemia, and infection, which are key components of the WIfI score, but does not provide the complete WIfI stage. The aim of this study is to validate the WIfI classification in the VQI PVI database and analyze the different combinations of components.
Methods: The VQI PVI data files (2013-2024) were reviewed for patients with CLTI with available data from which to derive WIfI scores. The characteristics of patients who underwent major amputation during follow-up were compared to those who did not. Kaplan-Meier curves were compared for major amputation, reintervention, and mortality for the various WIfI stages. Cox regression analysis was performed to assess for independent risk factors associated with major amputation RESULTS: A total of 280,706 individuals underwent PVI procedures, and 130,575 presented with CLTI. WIfI stage derivation was possible for 33% (N=42,858) of patients, 28,727 of whom had long-term follow up and were included in this study. A total of 3,271 (11.4%) underwent major amputation after LER. Patients requiring amputation were significantly younger and more likely to be male, Hispanic, or African American compared to patients who did not undergo amputation. Patients in the amputation group were more likely to be affected by most risk factors, and presented with higher WIfI stages. On Kaplan-Meier analysis, the estimates of 1-year major amputation or mortality significantly increased with each WIfI stage (stage 1=7.7%, stage 2=8.2%, stage 3=14.7%, stage 4=20.2% (p<0.001)). Cox regression analyses demonstrated that WIfI clinical stage (stage 2 vs 1, HR = 1.17[1.06-1.27], stage 3 vs 1, HR= 1.41[1.31-1.54], stage 4 vs 1, HR=1.69 [1.54 - 1.82]), and ESRD (HR=1.96 [1.8 - 2.14]) were independently associated with major amputation or mortality.
Conclusion: In conclusion, this study validated the WIfI classification in the VQI PVI database, confirming its value in predicting major amputation and mortality in patients with CLTI. Higher WIfI stages were independently associated with increased risk of major amputation and mortality, highlighting the importance of capturing and integrating the WIfI score into all VQI modules related to treatment of PAD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvs.2025.03.001 | DOI Listing |
Ann Vasc Surg
March 2025
Center for Learning and Excellence in Vascular and Endovascular Surgery (CLEVER), Department of Surgery, Division of Vascular and Endovascular Surgery, University of California San Diego Health System, San Diego, CA. Electronic address:
Introduction: This study aims to evaluate perioperative and one-year outcomes of patients undergoing aortobiiliac bypass (ABIB) in comparison with aortobifemoral bypass (ABFB) for the treatment of aortoiliac occlusive disease, using data from the Vascular Quality Initiative (VQI).
Methods: All patients undergoing ABIB and ABFB bypasses (2010-2023) were queried. The primary outcome was surgical site infections (SSI).
Cureus
February 2025
General Medicine, SVS Medical College, Mahabubnagar, IND.
Diabetic foot ulcers (DFUs) are severe complications of diabetes mellitus that often lead to nontraumatic limb amputation. This systematic review aimed to assess the primary clinical evidence supporting hyperbaric oxygen therapy (HBOT) in the management of DFUs. A literature search was conducted using PubMed, Scopus, and Web of Science from June to August 2024, and six studies with a total of 391 patients were included in the final analysis, after applying relevant inclusion and exclusion criteria.
View Article and Find Full Text PDFJ Soc Cardiovasc Angiogr Interv
January 2025
Yale Cardiovascular Research Group, Division of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Background: To understand the relative safety and efficacy of endovascular treatment modalities used for superficial femoral artery (SFA) disease, we performed a network meta-analysis to compare outcomes between percutaneous transluminal angioplasty (PTA), atherectomy (A), bare metal stent (BMS), brachytherapy/radiotherapy, covered stent graft (CSG), cutting balloon angioplasty (CBA), drug-coated balloon (DCB), drug-eluting stent (DES), and intravascular lithotripsy (L).
Methods: We performed a systematic literature search of PubMed from January 2000 to January 2023 to identify randomized trials comparing endovascular interventions for the treatment of SFA disease. The primary end points were technical success and 12-month primary patency.
J Vasc Nurs
March 2025
University of Maryland Medical Center, 22 South Greene Street Baltimore, MD, USA. Electronic address:
Problem: The Vascular Surgery department at a large academic institution lacked a formalized approach to manage complex pain experienced by patients undergoing major limb amputation (MLA). Consequently, MLA patients averaged 2,352.2 total morphine milliequivalent (MME) and had prolonged hospitalizations averaging 21 days.
View Article and Find Full Text PDFAnn Vasc Surg
March 2025
Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA. Electronic address:
Background: Peripheral artery disease (PAD) is widely prevalent, affecting more than 200 million people worldwide. However, the natural history of this disease process following lower extremity revascularization has not been fully delineated. We aimed to analyze this disease process with particular attention to subsequent interventions, wound complications, and mortality.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!